Shareholders have approved the Adcock Ingram takeover by Natco Pharma, marking a new chapter for the pharmaceutical company.
You must be a subscriber to access all of this content.
Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.
You must be a subscriber to access all of this content.
The recent R15.5 billion ARV tender sidelines Pharma Giants in South Africa, raising questions about local production support.
You must be a subscriber to access all of this content.
Learn how Bidvest's partnership with Natco Pharma impacts Adcock Ingram and shareholder rights amid a new takeover bid.
You must be a subscriber to access all of this content.
Adcock Ingram is set to delist from the JSE as Natco Pharma partners with Bidvest in a major take-private deal.
You must be a subscriber to access all of this content.